Details of a Researcher - Chiyoda, Tatsuyuki

Papers - Chiyoda, Tatsuyuki

Division display 1 - 20 of about 85 ／ All the affair displays >>

Sentinel node navigation surgery in cervical cancer: a systematic review and metaanalysis.

Chiyoda T, Yoshihara K, Kagabu M, Nagase S, Katabuchi H, Mikami M, Tabata T, Hirashima Y, Kobayashi Y, Kaneuchi M, Tokunaga H, Baba T.

Int J Clin Oncol. 27 ( 8 ) 1247 - 1255 2022.08

Lead author, Accepted

Evaluation of the Role of Intraoperative Frozen Section and Magnetic Resonance Imaging in Endometrial Cancer.

Ooka R, Nanki Y, Yamagami W, Kawaida M, Nagai S, Hirano T, Sakai K, Makabe T, Chiyoda T, Kobayashi Y, Kataoka F, Aoki D

Int J Gynaecol Obstet. 2022.08

Real-world application of next-generation sequencing-based test for surgically resectable colorectal cancer in clinical practice.

Ogiri M, Seishima R, Nakamura K, Aimono E, Matsui S, Shigeta K, Chiyoda T, Tanishima S, Okabayashi K, Nishihara H, Kitagawa Y.

Future Oncol. 2022.07

Efficacy and safety of Olaparib maintenance monotherapy for Japanese patients with platinum-sensitive relapsed ovarian, fallopian tube, and primary peritoneal cancer.

Yoshihama T, Kuroda Y, Chiyoda T, Takahashi M, Yoshimura T, Saotome K, Nanki Y, Sakai K, Kobayashi Y, Yamagami W, Aoki D.

Int J Clin Oncol. 2022.07

Corresponding author

Discrepancies in pathological diagnosis of endometrial stromal sarcoma: a multi-institutional retrospective study from the Japanese clinical oncology group

Yoshida H., Kikuchi A., Tsuda H., Sakamoto A., Fukunaga M., Kaku T., Yoshida M., Shikama A., Kogata Y., Terao Y., Tanikawa M., Yasuoka T., Chiyoda T., Miyamoto T., Okadome M., Nakamura T., Enomoto T., Konno Y., Yahata H., Hirata Y., Aoki Y., Tokunaga H., Usui H., Yaegashi N.

Human Pathology (Human Pathology) 124 24 - 35 2022.06

ISSN 00468177

Endometrial stromal sarcoma (ESS) is a rare uterine malignancy that requires accurate pathological diagnosis for proper treatment. This study aimed to clarify the discrepancies in the pathological diagnosis of ESS and obtain practical clues to improve diagnostic accuracy. Between 2002 and 2015, 148 patients with low-grade ESS (LGESS), high-grade ESS (HGESS), undifferentiated endometrial sarcoma (UES), or undifferentiated uterine sarcoma (UUS) diagnosed at 31 institutions were included. We performed immunohistochemistry, real-time polymerase chain reaction for JAZF1-SUZ12 and YWHAE-NUTM2A/B, and break-apart fluorescent in situ hybridization for JAZF1, PHF1, and YWHAE. Central pathology review (CPR) was performed by six pathologists. After CPR, LGESS, HGESS, UES/UUS, and other diagnoses were confirmed in 72, 25, 16, and 31 cases, respectively. Diagnostic discrepancies were observed in 19.6% (18/92) of LGESS and 34% (18/53) of HGESS or UUS/UES. Adenosarcomas, endometrial carcinomas, carcinosarcomas, and leiomyosarcomas were common diagnostic pitfalls. JAZF1-SUZ12 transcript, PHF1 split signal, and YWHAE-NUTM2A/B transcript were mutually exclusively detected in 23 LGESS, 3 LGESS, and 1 LGESS plus 3 HGESS, respectively. JAZF1-SUZ12 and YWHAE-NUTM2A/B transcripts were detected only in cases with CPR diagnosis of LGESS or HGESS. The CPR diagnosis of LGESS, HGESS, and UUS was a significant prognosticator, and patients with LGESS depicted a favorable prognosis, while those with UUS showed the worst prognosis. Pathological diagnosis of ESS is often challenging and certain tumors should be carefully considered. The accurate pathological diagnosis with the aid of molecular testing is essential for prognostic prediction and treatment selection.

Access to Document (DOI)

Characteristics and clinicopathological features of patients with ovarian metastasis of endometrial cancer: a retrospective study.

Matoba Y, Yamagami W, Chiyoda T, Kobayashi Y, Tominaga E, Banno K, Aoki D

J Obstet Gynaecol. 2022.06

<i>TP53</i> variants in p53 signatures and the clonality of STICs in RRSO samples.

Akahane T, Masuda K, Hirasawa A, Kobayashi Y, Ueki A, Kawaida M, Misu K, Nakamura K, Nagai S, Chiyoda T, Yamagami W, Hayashi S, Kataoka F, Banno K, Sugano K, Okita H, Kosaki K, Nishihara H, Aoki D

Journal of gynecologic oncology 2022.03

ISSN 2005-0380

Access to Document (DOI)

Clinical Usefulness of Endometrial Cytology in Determining the Therapeutic Effect of Fertility Preserving Therapy.

Takuma Yoshimura, Wataru Yamagami, Mio Takahashi, Takuro Hirano, Kensuke Sakai, Takeshi Makabe, Tatsuyuki Chiyoda, Kouji Banno, Daisuke Aoki

Acta cytologica (Acta Cytologica) 66 ( 2 ) 106 - 113 2022.03

ISSN 00015547

INTRODUCTION: The significance of endometrial cytology in determining the therapeutic efficacy of medroxyprogesterone acetate (MPA) therapy is unclear. This study aimed to evaluate the clinical usefulness of endometrial cytology during MPA therapy. METHODS: Overall, 77 patients who underwent dilatation and curettage (D&C) to evaluate the therapeutic efficacy of MPA therapy at our hospital between January 2018 and December 2019 were retrospectively analyzed. The results of D&C, cytological evaluation, and other clinicopathological factors were analyzed based on the patients' medical records. RESULTS: The sensitivity and specificity of cytology were 61% and 92%, respectively, with D&C being the gold standard for diagnosis in 142 D&C/cytological examinations. Among patients with no residual disease on D&C, 5 (4%) had suspicious or positive cytology. Although MPA therapy was terminated in 3 of these patients, only 1 patient had early recurrence, and the frequency of recurrence was similar to that of patients who showed negative results in both D&C and cytology. DISCUSSION/CONCLUSION: The sensitivity of endometrial cytology in determining the therapeutic effect of MPA therapy is low, and we confirmed that the omission of D&C is unacceptable. Our findings also suggested that the addition of cytological evaluation to D&C during MPA therapy had a low clinical significance.

Access to Document (DOI)

p53 dysfunction hampers the differentiation of mouse fallopian tube organoids

Nagai Shimpei, Masuda Kenta, Tamura Tomohiro, Otsuki Yuji, Suina Kentaro, Nobusue Hiroyuki, Akahane Tomoko, Chiyoda Tatsuyuki, Kobayashi Yusuke, Banno Kouji, Aoki Daisuke, Saya Hideyuki, Nagano Osamu

CANCER SCIENCE 113 1282 - 1282 2022.02

ISSN 1347-9032

Prospective feasibility study of neoadjuvant dose-dense paclitaxel plus carboplatin with bevacizumab therapy followed by interval debulking surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer patients.

Naomi Iwasa-Inoue, Hiroyuki Nomura, Fumio Kataoka, Tatsuyuki Chiyoda, Tomoko Yoshihama, Yoshiko Nanki, Kensuke Sakai, Yusuke Kobayashi, Wataru Yamagami, Tohru Morisada, Akira Hirasawa, Daisuke Aoki

International journal of clinical oncology (International Journal of Clinical Oncology) 27 ( 2 ) 441 - 447 2022.02

ISSN 13419625

BACKGROUND: This study aimed to investigate the clinical benefit of dose-dense paclitaxel plus carboplatin (TC) with bevacizumab therapy for advanced ovarian, fallopian tube, and primary peritoneal cancer patients in the neoadjuvant setting. METHODS: Ovarian, fallopian tube or primary peritoneal cancer patients with stage III-IV disease received neoadjuvant chemotherapy (NAC) every 3 weeks consisting of paclitaxel (80 mg/m2) on days 1, 8, and 15; carboplatin (AUC 6.0 mg/mL × min.) on day 1; and bevacizumab (15 mg/kg) on day 1. Interval debulking surgery (IDS) was performed after 3 cycles of dose-dense TC-bevacizumab therapy. The primary endpoint was the rate of complete resection by IDS. Secondary endpoints were treatment completion rate, treatment exposure, response rate to NAC, adverse events, and perioperative complications. RESULTS: Twenty-four patients were included in this study. The median age was 55.5 years (37-80 years), and most patients had high-grade serous carcinoma accounted (n = 18). IDS was performed in all patients with complete resection achieved in 75% (95% confidence interval: 57.7-92.3%). The lower limit exceeded the preset threshold rate of 55%. The response rate to NAC was 79%, and serum CA125 levels were in the normal range after NAC in 57% of patients. Grade 4 hematological toxicities and grade 3/4 non-hematological toxicities occurred in 29% and 17% of patients during NAC, respectively. Grade 3/4 perioperative complications were seen in 29% of patients, but no gastrointestinal perforations or treatment-related deaths occurred. CONCLUSIONS: Neoadjuvant dose-dense TC-bevacizumab therapy was well tolerated, and a satisfactory rate of complete resection by IDS was achieved.

Access to Document (DOI)

Sentinel node navigation surgery in cervical cancer: a systematic review and metaanalysis.

Tatsuyuki Chiyoda, Kosuke Yoshihara, Masahiro Kagabu, Satoru Nagase, Hidetaka Katabuchi, Mikio Mikami, Tsutomu Tabata, Yasuyuki Hirashima, Yoichi Kobayashi, Masanori Kaneuchi, Hideki Tokunaga, Tsukasa Baba

International journal of clinical oncology (International Journal of Clinical Oncology) 2022

ISSN 13419625

Sentinel node navigation surgery (SNNS) is used in clinical practice for the treatment of cervical cancer. This study aimed to elucidate the appropriate sentinel lymph node (SLN) mapping method and assess the safety and benefits of SNNS. We searched the PubMed, Ichushi, and Cochrane Library databases for randomized controlled trials (RCT) and studies on SLN in cervical cancer from January 2012 to December 2020. Two authors independently assessed study quality and extracted data. We quantitatively analyzed the detection rate, sensitivity/specificity, and complications and reviewed information, including the survival data of SLN biopsy (SLNB) without pelvic lymphadenectomy (PLND). The detection rate of SLN mapping in the unilateral pelvis was median 95.7% and 100% and in the bilateral pelvis was median 80.4% and 90% for technetium-99 m (Tc) with/without blue dye (Tc w/wo BD) and indocyanine green (ICG) alone, respectively. The sensitivity and specificity of each tracer were high; the area under the curve of each tracer was 0.988 (Tc w/wo BD), 0.931 (BD w/wo Tc), 0.966 (ICG), and 0.977 (carbon nanoparticle). Morbidities including lymphedema, neurological symptoms and blood loss were associated with PLND. One RCT and five studies all showed SNNS without systematic PLND does not impair recurrence or survival in early-stage cervical cancer with a tumor size ≤ 2-4 cm. Both Tc w/wo BD and ICG are appropriate SLN tracers. SNNS can reduce the morbidities associated with PLND without affecting disease progression in early-stage cervical cancer.

Access to Document (DOI)

ESMO 2021 meeting report: Gynecologic cancer.

千代田達幸, 青木大輔

月刊腫瘍内科 29 ( 2 ) 2022

ISSN 1881-6568

ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer.

Yuka Kuroda, Tatsuyuki Chiyoda, Miho Kawaida, Kohei Nakamura, Eriko Aimono, Takuma Yoshimura, Mio Takahashi, Keiko Saotome, Tomoko Yoshihama, Naomi Iwasa, Kensuke Sakai, Wataru Yamagami, Hiroshi Nishihara, Daisuke Aoki

Gynecologic oncology (Gynecologic Oncology) 162 ( 3 ) 679 - 685 2021.09

Corresponding author, ISSN 00908258

OBJECTIVES: ARID1A mutation is frequently found in clear cell ovarian cancer (CCC) and endometrioid ovarian cancer (EC). Anti-PD-1 monotherapy has been found to have limited efficacy in epithelial ovarian cancer; however, anti-PD-1 therapy showed significant clinical benefit in some CCC. We sought to define the relationship of ARID1A mutation/ARID1A expression to the immunogenic profile of different histologic subtypes of ovarian cancer. METHODS: We performed next-generation sequencing of 160 cancer-related genes. Also, we analyzed the immunohistochemical status of ARID1A, PD-L1, and CD8 with survival in different histologic subtypes of ovarian cancer in a total of 103 cases. RESULTS: ARID1A mutation was found in 0% of the high-grade serous ovarian cancer (HGSC) (n = 36), 41.5% of the CCC (n = 41), 45.0% of the EC (n = 20), and 33.3% of the mucinous ovarian cancer (MC) (n = 6) cases. ARID1A loss was found in 19.4% of the HGSC, 75.6% of the CCC, 60.0% of the EC and 0% of the MC cases. ARID1A mutation was found to be associated with high PD-L1 (p < 0.001) or CD8 levels (p < 0.001) in CCC but not in other histologic subtypes. Meanwhile, ARID1A loss was associated with high PD-L1 or CD8 levels in CCC (p < 0.001) and HGSC (p < 0.001) but not in EC and MC. In addition, ARID1A mutation was associated with high tumor mutation burden in CCC (p = 0.006). CONCLUSIONS: ARID1A mutation/ARID1A expression is associated with immune microenvironmental factors in CCC but not in EC. ARID1A status can be a biomarker for selecting candidates for immune checkpoint blockade in CCC.

Access to Document (DOI)

当院で経験した子宮体部大細胞神経内分泌癌(LCNEC)の3例

平松真生子, 山上亘, 平野卓朗, 吉村拓馬, 千代田達幸, 西尾浩, 仲村勝, 阪埜浩司, 田中守, 青木大輔

東京産科婦人科学会会誌 ((一社)東京産科婦人科学会) 70 ( 3 ) 493 - 497 2021.07

ISSN 2186-0599

子宮体部原発の大細胞神経内分泌癌(large cell neuroendocrine carcinoma:LCNEC)は稀で予後不良な組織型である。当院で経験した子宮体部LCNEC 3例につき報告する。症例1〜3は51〜75歳。術前に症例1、2は神経内分泌腫瘍を、症例3は癌肉腫を疑い手術を施行し、症例1は不完全切除、症例2、3は完全切除であった。手術進行期は症例1がIVB期、症例2がIIIB期、症例3がIIIC2期で、組織型はいずれもLCNECであったが、症例3のみ一部肉腫様成分が混在した。術後に症例1はpaclitaxel+carboplatin療法を、症例2、3はirinotecan+cisplatin療法を施行し、症例1、2は1年以内に再発したが、症例3は52ヵ月無再発で経過している。子宮体部LCNECは予後不良だが、完全切除可能で他組織型が併存する症例は予後良好である可能性がある。(著者抄録)

特集卵巣癌におけるHRDとPARP阻害薬の効果 11.再発治療時のオラパリブとニラパリブのエビデンス

千代田達幸, 青木大輔

産婦人科の実際 (金原出版) 70 ( 5 ) 537 - 544 2021.05

ISSN 0558-4728

Estimating copy number using next-generation sequencing to determine ERBB2 amplification status

Nakamura K, Aimono E, Oba J, Hayashi H, Tanishima S, Hayashida T, Chiyoda T, Kosaka T, Hishida T, Kawakubo H, Kitago M, Okabayashi K, Funakoshi T, Okita H, Ikeda S, Takaishi H, Nishihara H

Medical Oncology (Medical Oncology) 38 ( 4 ) 36 - 36 2021.04

ISSN 13570560

© 2021, The Author(s). Assessing Erb-b2 receptor tyrosine kinase 2 (ERBB2) amplification status in breast and gastric cancer is necessary for deciding the best therapeutic strategy. Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are currently used for assessing protein levels and gene copy number (CN), respectively. The use of next-generation sequencing (NGS) to measure ERBB2 CN in breast cancer is approved by the United States Federal Drug Administration as a companion diagnostic. However, a CN of less than 8 is evaluated as “equivocal”, which means that some ERBB2 amplification cases diagnosed as “HER2 negative” might be false-negative cases. We reviewed the results of gene profiling targeting 160 cancer-related genes in breast (N = 90) and non-breast (N = 19) cancer tissue, and compared the ERBB2 CN results with the IHC/FISH scores. We obtained an estimated CN from the measured CN by factoring in the histological proportion of tumor cells and found that an ERBB2-estimated CN of 3.2 or higher was concordant with the combined IHC/FISH outcome in 98.4% (88/90) of breast cancer cases, while this was not always evident among non-breast cancer cases. Therefore, NGS-estimated ERBB2 CN could be considered a diagnostic test for anti-HER2 therapy after the completion of adequate prospective clinical trials.

Access to Document (DOI)

Retrospective evaluation of risk-reducing salpingo-oophorectomy for BRCA1/2 pathogenic variant carriers among a cohort study in a single institution

Kobayashi Y, Hirasawa A, Chiyoda T, Ueki A, Masuda K, Misu K, Kawaida M, Hayashi S, Kataoka F, Banno K, Kosaki K, Aoki D

Japanese journal of clinical oncology (Japanese journal of clinical oncology) 51 ( 2 ) 213 - 217 2021.02

ISSN 0368-2811

© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com. BACKGROUND: Risk-reducing salpingo-oophorectomy is performed for the primary prevention of ovarian cancer in patients with hereditary breast-ovarian cancer syndrome. We performed risk-reducing salpingo-oophorectomy for the first time in Japan in 2008, and we experienced 20 cases of risk-reducing salpingo-oophorectomy through 2019. In the past, the use of risk-reducing salpingo-oophorectomy in Japan was restricted because it was not covered by a Japanese National Health Insurance. Since April 2020, risk-reducing salpingo-oophorectomy has been covered by insurance for patients with breast-ovarian cancer syndrome and pre-existing breast cancer, and this surgery is expected to become more widely implemented in Japan. METHODS: To contribute to the widespread use of risk-reducing salpingo-oophorectomy in the future, we retrospectively reviewed 20 cases of risk-reducing salpingo-oophorectomy at our hospital cohort study to clarify the issues in its implementation. RESULTS: The variant genes for which risk-reducing salpingo-oophorectomy was indicated were BRCA1 and BRCA2 in 13 (65%) and 7 patients (35%), respectively. The median age at which risk-reducing salpingo-oophorectomy was performed was 49 years (range, 38-58), 13 patients (65%) had gone through menopause, and 16 patients (80%) had a history of breast cancer. Of the five patients (25%) with vasomotor symptoms, four received Chinese medicine, and only one received hormone replacement therapy. Occult cancer was detected in the removed ovaries in two patients (10%), although no postoperative peritoneal carcinogenesis has been observed to date. CONCLUSIONS: Women who paid for risk-reducing salpingo-oophorectomy out of pocket were older than the recommended age at which the procedure should be performed, and this may explain the higher rate of occult cancers than previously reported. We need to perform risk-reducing salpingo-oophorectomy at the recommended age to ensure that the procedure is effective for primary prevention.

Access to Document (DOI)

Ovarian cancer organoids recapitulate genomic alterations of the parental tumors.

Nanki Yoshiko, Chiyoda Tatsuyuki, Hirasawa Akira, Ookubo Aki, Itoh Manabu, Yoshimura Takuma, Akahane Tomoko, Yamagami Wataru, Aoki Daisuke

CANCER SCIENCE 112 450 - 450 2021.02

ISSN 1347-9032

A prospective cohort study on the safety and efficacy of bevacizumab combined with chemotherapy in Japanese patients with relapsed ovarian, fallopian tube or primary peritoneal cancer

Nanki Y, Nomura H, Iwasa N, Saotome K, Dozen A, Yoshihama T, Hirano T, Hashimoto S, Chiyoda T, Yamagami W, Kataoka F, Aoki D

Japanese Journal of Clinical Oncology (Japanese Journal of Clinical Oncology) 51 ( 1 ) 54 - 59 2021.01

ISSN 03682811

© The Author(s) 2020. Published by Oxford University Press. All rights reserved. Objective: this prospective cohort study aimed to assess the safety and efficacy of bevacizumab combined with chemotherapy in Japanese patients with relapsed ovarian, fallopian tube or primary peritoneal cancer. Methods: in this study, 40 Japanese patients with relapsed ovarian, fallopian tube or primary peritoneal cancer selected to receive bevacizumab with chemotherapy were enrolled. Patients in poor general condition were excluded. Each patient was monitored prospectively for adverse events, administration status, disease status and survival. Treatment was continued until intolerable adverse events or disease progression. The primary endpoint was safety. Results: bevacizumab plus platinum-based chemotherapy was performed for 30 patients (median cycle; 16.5), while bevacizumab plus non-platinum chemotherapy was performed for 10 patients (median cycle; 5.5). Among bevacizumab-related adverse events, hypertension occurred in 80% of patients, proteinuria in 83%, mucositis in 25%, bleeding in 20%, thromboembolic events in 5.0% and fistula in 2.5%. Gastrointestinal perforation or other life-threatening lethal adverse events were not observed. Response rate and median progression-free survival were 73% and 19.3 months for patients with bevacizumab plus platinum-based chemotherapy, and 30% and 3.9 months for patients with bevacizumab plus non-platinum chemotherapy, respectively. There was no correlation between response rate and occurrence of adverse events such as hypertension or proteinuria. Conclusion: bevacizumab combined with chemotherapy was tolerable and effective for Japanese patients with relapsed ovarian cancer, fallopian tube cancer or primary peritoneal cancer. Hypertension and proteinuria are frequently occurred and managed properly for continuing treatment.

Access to Document (DOI)

Atypical vessels in hysteroscopy: Usefulness in prediction of malignant diseases in patients treated with tamoxifen

Oka E, Sakai K, Yamagami W, Hirano T, Makabe T, Yoshihama T, Chiyoda T, Kataoka F, Banno K, Aoki D

Journal of Obstetrics and Gynaecology Research (Journal of Obstetrics and Gynaecology Research) 47 ( 4 ) 1510 - 1515 2021

ISSN 13418076

© 2021 Japan Society of Obstetrics and Gynecology Aim: Tamoxifen (TAM) is widely used in adjuvant endocrine therapy for invasive breast cancer as a selective estrogen modulator, but this treatment has a risk of developing endometrial malignancy. However, hysteroscopic findings during or after TAM treatment are unclear. The aim of this study is to examine the association between hysteroscopic patterns and malignant histological findings during or after treatment with TAM. Methods: The subjects were patients who received TAM after surgery for breast cancer and underwent hysteroscopy at our institution from January 2016 to December 2019. Clinicopathological factors and hysteroscopic findings were collected from medical records and investigated retrospectively. Histologically, atypical endometrial hyperplasia, endometrial cancer, and carcinosarcoma were classified as malignant diseases. Results: A total of 26 patients were eligible for the study. Hysteroscopic findings included an irregular surface of the endometrium (n = 3, 11.5%), atypical vessels (n = 10, 38.5%), papillary structure (n = 3, 11.5%), and polypoid structure (n = 18, 69.2%). Histological examination revealed malignancy in six patients (23.0%). The percentage of atypical vessels in patients with malignancies was significantly higher than that in patients with a normal endometrium or benign lesion (100% vs. 20%, p = 0.0009). The sensitivity and specificity of atypical vessels in hysteroscopy for diagnosis of malignant diseases were 100% and 80%, respectively. Conclusions: Hysteroscopic findings of atypical vessels may be useful for prediction of malignant diseases in patients treated with TAM.

Access to Document (DOI)

　 Previous page - Next page 　